Mechanisms of Immune Checkpoint Resistance Mediated by LKB1 Tumor Suppressor in Lung Cancer
Abstract
LKB1 is one of the most commonly lost tumor suppressors in lung cancer, with 30 percent loss in lung adenocarcinomas. It has recently been demonstrated that NSCLC patients with LKB1 loss have significantly worse outcomes to immune based treatment strategies, with lower response rates and decreased progression free and overall survival. Determining the mechanism for this immune refractory phenotype and a strategy to overcome it are urgent and unmet clinical needs. This report will demonstrate progress characterizing LKB1-add back isogenic derivatives of immune resistant LKB1 mutant cell lines as model systems for study of LKB1-deficient immune resistance, the use of high throughput functional genomics approaches to identify candidate genes and pathways that may confer resistance, and preliminary validation of candidate mechanisms resulting from these experiments.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2021
- Accession Number
- AD1164049
Entities
People
- Jacob Kaufman
Organizations
- Duke University